Navigation Links
Global and China Monoclonal Antibody Industry Report 2013 Analysis and 2017 Market Focus by Researchmoz.us
Date:12/25/2013

Albany, NY (PRWEB) December 25, 2013

Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents grew at a CAGR of 13%, far higher than the overall growth rate of biopharmaceuticals in the same period.

Browse Full Report With TOC at: http://www.researchmoz.us/global-and-china-monoclonal-antibody-industry-report-2013-2017-report.html

Thanks to robust market demand, approval of new products and new indications as well as launch of monoclonal antibody generic drugs, the global monoclonal antibody market size will ascend by more than 12% in 2013-2017, hitting USD141 billion in 2017.

Driven by enhanced economic level, expanded scope of medical insurance reimbursement, as well as lower prices incurred by intensified competition, Chinese monoclonal antibody market is expected to continue to grow significantly. In 2013-2017, Chinese monoclonal antibody market will grow at 35%, sharing 21.5% of the global monoclonal antibody market in 2017 (9.5% in 2012).

The global monoclonal antibody industry is still dominated by European and American companies, especially, important monoclonal antibody products are mainly produced by Roche (Genentech), Amgen, AbbVie (Abbott), Johnson & Johnson and other companies. In 2012, the global best-selling Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (AbbVie) and Trastuzumab (Roche) stemmed from the above four companies. The global sales (including the sales of third parties) of these six monoclonal antibody agents totaled USD45 billion, accounting for 57.7% of the global.

Find More Reports from Research in China Publisher at: http://www.researchmoz.us/publisher/research-in-china-67.html

In recent years, China monoclonal antibody industry has been developing fast with the market size CAGR of 44.6% in 2010-2012. More than 100 companies have been involved in monoclonal antibody agents, and 10 ones of them have conducted clinical applications. The Chinese market is dominated by Rituximab, Trastuzumab, Infliximab, Bevacizumab and other imported products, all of which occupied 70-75% market share totally in 2012.

However, by virtue of price and geographical advantages, the competitiveness of Chinese local monoclonal antibody products has been gradually improved, such as the competition between Nimotuzumab and Cetuximab. The market share of Merck's Cetuximab in China shrinks and was excluded from top 200 drugs purchased by Chinese 22 typical urban hospitals in 2012 with the value of RMB130 million (down 16.35% year on year).

Related Reports:-

Global Bioinformatics Market 2014-2018

Global Bioinformatics market to grow at a CAGR of 26.15 percent over the period 2013-2018. One of the key factors contributing to this market growth is the decreasing cost of genetic sequencing. The Global Bioinformatics market has also been witnessing the increasing outsourcing of bioinformatics services. However, the complexity in using bioinformatics tools could pose a challenge to the growth of this market. The Global Bioinformatics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC region; it also covers the Global Bioinformatics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Browse Full Report with TOC at: http://www.researchmoz.us/global-bioinformatics-market-2014-2018-report.html
China Heparin Industry Report, 2013-2015

Since the small intestines of pigs (raw materials for production of heparin) in China are abundant (the pig slaughtering volume in China approximates 50% of globe’s total) and heparin APIs are gradually recognized internationally, China has grown into the largest heparin API producing and exporting country around the globe. Nevertheless, due to the stagnant demand in European and American markets in recent two years and the improved standards for heparin export, the export volume and value of heparin APIs in China both presented a decline trend during 2011-2012.
Browse Full Report wtih TOC at: http://www.researchmoz.us/china-heparin-industry-report-2013-2015-report.html

About Us:

ResearchMoz ( http://www.researchmoz.us/ ) is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning.

For More Information Kindly Contact:
Mrs.Sheela AK
Tel:+1-518-618-1030
Toll Free: 866-997-4948
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Email: sales(at)researchmoz(dot)us
Blog: http://researchmoz.blogspot.com/

Read the full story at http://www.prweb.com/releases/2013/12/prweb11446822.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. NIH awards $20 million over 5 years to train next generation of global health researchers
2. Canada should play a role in addressing the global cancer epidemic
3. Global cardiology leaders meet in Dubai
4. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
5. International breast health global summit will focus on supportive care and quality of life
6. Scientists rewrite rulebook on breast cancer in landmark global study
7. Global CVD leaders call the world to action - 25 by 2025 - from the World Congress of Cardiology
8. Centre for Global Non-Communicable Diseases launched to tackle killer diseases
9. UCLA researchers combat global disease with a cell phone, Google Maps and a lot of ingenuity
10. New study identifies how information technology is used to solve global health challenges
11. New global report says US lags behind 130 other nations in preterm birth rate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... ... firm and statement solutions provider, for the tenth consecutive year as a ... issue of Advertising Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing ...
(Date:5/31/2016)... ... May 31, 2016 , ... CURE ... patients with cancer, has added Cancer and Careers to its ... timely content on continuing successful careers while fighting cancer. , As partners, both ...
(Date:5/30/2016)... ... ... As the CDC relaxes its stance on traditional No-Nit policies, parents wonder what ... free. , According to a May 26 article from news source KHON2 ... despite the fact that they may be harboring an infestation. Previous No-Nit policies stated ...
(Date:5/30/2016)... ... May 30, 2016 , ... Zane Benefits, the leader ... an original infographic, " Health Benefits Reimbursement Compliance Timeline ." , The ... complies with various federal regulations and reforms. , Navigating the new health reforms ...
(Date:5/30/2016)... ... May 30, 2016 , ... Another ER facility operated ... Plano, located at 3960 Legacy Drive, Plano, TX and is open 24 hours daily. ... Commerce followed by a medical open house. The Jasper High School band entertained attendees ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... , May 30, 2016 ... reach USD 7.3 billion by 2024, according to ... The increasing natality rate, the growing malnutrition coupled ... cancer and gastro-intestinal tract diseases are expected to ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ...
(Date:5/30/2016)... LifeScienceIndustryResearch.com adds "Ulcerative Colitis ... with comprehensive information on the therapeutic development for ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Ulcerative Colitis ...
(Date:5/27/2016)... LabStyle Innovations Corp . ( ... today announced that the Company,s Chief Financial Officer, Zvi ... held June 1-2 in New York, NY ... in Los Angeles, CA. ... operational milestones, including the U.S. FDA Clearance and commercial launch ...
Breaking Medicine Technology: